Loading the page…
Nasdaq 100
ALNY
Alnylam Pharmaceuticals, Inc., Health Care
$165.00
−5.17% on the day
Close of Fri, Oct 30, 2026
−19.7% over 3M
2026-07-312026-09-162026-10-30
Market cap$22.1B
Last close$165.00
Day move
Nasdaq 100
Alnylam Pharmaceuticals, Inc., Health Care
$165.00
−5.17% on the day
Close of Fri, Oct 30, 2026
| Quarter ending | Jun 2026 | Sep 2025 | Jun 2025 | Dec 2024* | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023* |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3B | $1.2B | $774M | $593M | $501M | $660M | $494M | $440M |
| Gross margin | 76.9% | 84.2% | 81.6% | 82.7% | 83.6% | 89.8% | 89.0% | 83.6% |
| Operating margin | 17.9% | 29.5% | -2.1% | -17.7% | -15.4% | 7.4% | -8.8% | -26.5% |
| Net margin | 12.7% | 20.1% | -9.3% | -14.1% | -22.3% | -2.6% | -13.3% | -31.4% |
| EPS, diluted | $1.21 | $1.84 | −$0.55 | −$0.66 | −$0.87 | −$0.13 | −$0.52 | −$1.06 |
From the company's SEC filings, newest first. * A fiscal fourth quarter: the year's 10-K less its first three quarters.
The same ranks the builder's sliders blend. Small and Wild are Big and Calm turned over.
| Measure | ALNY | Higher than |
|---|---|---|
| Earnings yield (earnings ÷ price) | 3.5% | 62% |
| Book yield (book value ÷ price) | 6.1% | 24% |
| Free cash flow yield | 2.1% | 42% |
| Buyback yield | 0.0% | 0% |
| Revenue growth, a year | 65.2% | 92% |
| EPS growth, a year | 206.9% | 89% |
| Return on equity | 57.2% | 85% |
| Return on assets | 13.9% | 63% |
| Net margin | 20.9% |
Research
Figures from SEC filings and daily closes; results dates and headlines from Yahoo Finance and Nasdaq; insider trades from SEC Form 4. For learning, not investment advice.
| 57% |
| Liabilities ÷ assets | 75.6% | 85% |
|---|
| Past year, skipping last month | -52.0% | 2% |
|---|
| Past 6 months, skipping last month | -21.9% | 6% |
|---|
| Volatility, a year's worth | 66.9% | 83% |
|---|
"Higher than" is the share of the 100 with a lower figure. Financial figures from SEC filings, market figures from daily closes. Dividend yield and beta are under Valuation below.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.
From Yahoo Finance, alnylam.com
5 Best High Growth Stocks Outside Big TechInsider Monkey, 5h ago
Alnylam (ALNY) Stock Drops As Q3 Earnings Clash With Sales ConcernsSimply Wall St., 22h ago
Alnylam Faces Near-Term Risk on Amvuttra, Oppenheimer SaysMT Newswires, Oct 30BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS SaysMT Newswires, Oct 30Alnylam Pharmaceuticals' Fundamentals Remain Strong Despite Lower-End Guidance Expectations, UBS SaysMT Newswires, Oct 30
What Just Happened To Alnylam Stock?Trefis, Oct 30Alnylam Q3 Update Disappoints as TTR Revenue Trends Toward Low End, RBC SaysMT Newswires, Oct 30
Global Ribonucleic Acid (RNA) Interference Technology Market Report 2026-2030 | Capitalize on Precision Gene Silencing with Alnylam, Arrowhead, Silence Therapeutics, and RocheGlobeNewswire, Oct 30Global Gene Silencing Therapeutics Market Report 2026-2030 | Capitalize on 16.3% CAGR as Novartis, Alnylam, Ionis, Sarepta, and Arrowhead Accelerate RNA DeliveryGlobeNewswire, Oct 30
ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth ConcernsZacks, Oct 30Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
5 Best High Growth Stocks Outside Big TechInsider Monkey, 5h agoAlnylam (ALNY) Stock Drops As Q3 Earnings Clash With Sales ConcernsSimply Wall St., 22h agoAlnylam Faces Near-Term Risk on Amvuttra, Oppenheimer SaysMT Newswires, Oct 30BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS SaysMT Newswires, Oct 30Alnylam Pharmaceuticals' Fundamentals Remain Strong Despite Lower-End Guidance Expectations, UBS SaysMT Newswires, Oct 30Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
Open-market buys and sells are the ones that say something; awards, exercises and tax withholding are routine.
Every transaction, in AdvancedSEC Form 4, public domain. The latest 40 of 45 Form 4 filings from the last 12 months are counted. A sale filled at several prices is one line at its average price. All Form 4s on EDGAR
Open-market buys and sells are the ones that say something; awards, exercises and tax withholding are routine.
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 2, 2026 | Supran BryanEVP, CLO and Secretary | Sold on the market | −1,758 | $226.88 | $399K | Form 4 ↗ |
| Sep 19, 2026 | Greenstreet YvonneCEO, Director | Award | +107 | — | — | Form 4 ↗ |
| Jun 1, 2026 | Pyott David E IDirector | Option exercise | +3,830 | — | — | Form 4 ↗ |
| Jun 1, 2026 | Pyott David E IDirector | Sold on the market10b5-1 plan | −3,830 | $299.18average | $1.1M | Form 4 ↗ |
| Jun 1, 2026 | Cravatt BenjaminDirector | AwardStock Option (Right to Buy) | +4,393 | — | — | Form 4 ↗ |
| May 20, 2026 | Sigal Charles ElliottDirector | Award | +671 | — | — | Form 4 ↗ |
| May 20, 2026 | Sigal Charles ElliottDirector | AwardStock Option (Right to Buy) | +1,441 | — | — | Form 4 ↗ |
| May 20, 2026 | Schulman Amy WDirector | Award | +838 | — | — | Form 4 ↗ |
| May 20, 2026 | Schulman Amy WDirector | AwardStock Option (Right to Buy) | +1,802 | — | — | Form 4 ↗ |
| May 20, 2026 | Reitan Colleen FDirector | Award | +671 | — | — | Form 4 ↗ |
| May 20, 2026 | Reitan Colleen FDirector | AwardStock Option (Right to Buy) | +1,441 | — | — | Form 4 ↗ |
| May 20, 2026 | Pyott David E IDirector | Award | +671 | — | — | Form 4 ↗ |
| May 20, 2026 | Pyott David E IDirector | AwardStock Option (Right to Buy) | +1,441 | — | — | Form 4 ↗ |
| May 20, 2026 | Kellogg Peter NDirector | Award | +671 | — | — | Form 4 ↗ |
| May 20, 2026 | Kellogg Peter NDirector | AwardStock Option (Right to Buy) | +1,441 | — | — | Form 4 ↗ |
| May 20, 2026 | Hamburg Margaret ADirector | Award | +671 | — | — | Form 4 ↗ |
| May 20, 2026 | Hamburg Margaret ADirector | AwardStock Option (Right to Buy) | +1,441 | — | — | Form 4 ↗ |
| May 20, 2026 | Brandicourt OlivierDirector | Award | +671 | — | — | Form 4 ↗ |
| May 20, 2026 | Brandicourt OlivierDirector | AwardStock Option (Right to Buy) | +1,441 | — | — | Form 4 ↗ |
| May 20, 2026 | Ausiello Dennis ADirector | Award | +671 | — | — | Form 4 ↗ |
| May 20, 2026 | Ausiello Dennis ADirector | AwardStock Option (Right to Buy) | +1,441 | — | — | Form 4 ↗ |
| May 20, 2026 | Arbuckle Stuart ADirector | Award | +671 | — | — | Form 4 ↗ |
| May 20, 2026 | Arbuckle Stuart ADirector | AwardStock Option (Right to Buy) | +1,441 | — | — | Form 4 ↗ |
| May 13, 2026 | Schulman Amy WDirector | Option exercise | +11,250 | $70.20 | $790K | Form 4 ↗ |
| Apr 6, 2026 | McLaughlin MelissaChief Human Resources Officer | Sold on the market10b5-1 plan | −2,286 | $330.42average | $755K | Form 4 ↗ |
| Apr 2, 2026 | McLaughlin MelissaChief Human Resources Officer | Sold on the market10b5-1 plan | −1,624 | $319.59average | $519K | Form 4 ↗ |
| Mar 5, 2026 | Garg PushkalEVP Chief R&D | Sold on the market10b5-1 plan | −2,404 | $323.96average | $779K | Form 4 ↗ |
| Mar 5, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Sold on the market10b5-1 plan | −658 | $323.98average | $213K | Form 4 ↗ |
| Mar 4, 2026 | Garg PushkalEVP Chief R&D | Sold on the market10b5-1 plan | −2,309 | $323.08average | $746K | Form 4 ↗ |
| Mar 4, 2026 | Greenstreet YvonneCEO, Director | Sold on the market | −2,933 | $323.08average | $948K | Form 4 ↗ |
| Mar 4, 2026 | Poulton Jeffrey V.EVP, CFO | Sold on the market | −2,468 | $323.08average | $797K | Form 4 ↗ |
| Mar 4, 2026 | Tanguler TolgaEVP, Chief Commercial Officer | Sold on the market | −2,309 | $323.08average | $746K | Form 4 ↗ |
| Mar 4, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Sold on the market10b5-1 plan | −633 | $323.08average | $205K | Form 4 ↗ |
| Mar 3, 2026 | Garg PushkalEVP Chief R&D | Sold on the market10b5-1 plan | −1,775 | $319.74average | $568K | Form 4 ↗ |
| Mar 3, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Sold on the market10b5-1 plan | −1,652 | $319.73average | $528K | Form 4 ↗ |
| Mar 2, 2026 | Poulton Jeffrey V.EVP, CFO | Award | +4,769 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Poulton Jeffrey V.EVP, CFO | Sold on the market | −2,206 | $327.65average | $723K | Form 4 ↗ |
| Mar 2, 2026 | Poulton Jeffrey V.EVP, CFO | AwardStock Option (right to buy) | +10,480 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Garg PushkalEVP Chief R&D | Award | +4,769 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Garg PushkalEVP Chief R&D | Sold on the market10b5-1 plan | −1,717 | $327.66average | $563K | Form 4 ↗ |
| Mar 2, 2026 | Garg PushkalEVP Chief R&D | AwardStock Option (right to buy) | +10,480 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Award | +3,688 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Sold on the market10b5-1 plan | −1,598 | $327.65average | $524K | Form 4 ↗ |
| Mar 2, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | AwardStock Option (right to buy) | +8,105 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Tanguler TolgaEVP, Chief Commercial Officer | Award | +4,769 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Tanguler TolgaEVP, Chief Commercial Officer | Sold on the market | −1,598 | $327.65average | $524K | Form 4 ↗ |
| Mar 2, 2026 | Tanguler TolgaEVP, Chief Commercial Officer | AwardStock Option (right to buy) | +10,480 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Supran BryanEVP, CLO and Secretary | Award | +1,539 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Supran BryanEVP, CLO and Secretary | AwardStock Option (right to buy) | +3,381 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Greenstreet YvonneCEO, Director | Award | +13,844 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Greenstreet YvonneCEO, Director | Sold on the market | −6,799 | $327.65average | $2.2M | Form 4 ↗ |
| Mar 2, 2026 | Greenstreet YvonneCEO, Director | AwardStock Option (right to buy) | +30,425 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Greenstreet YvonneCEO, Director | AwardStock Price Performance Stock Unit | +110,746 | — | — | Form 4 ↗ |
| Feb 27, 2026 | Greenstreet YvonneCEO, Director | Units vested | +5,921 | — | — | Form 4 ↗ |
| Feb 27, 2026 | Poulton Jeffrey V.EVP, CFO | Units vested | +1,908 | — | — | Form 4 ↗ |
| Feb 27, 2026 | Tanguler TolgaEVP, Chief Commercial Officer | Units vested | +1,666 | — | — | Form 4 ↗ |
| Feb 27, 2026 | Garg PushkalEVP Chief R&D | Units vested | +1,908 | — | — | Form 4 ↗ |
| Feb 27, 2026 | Garg PushkalEVP Chief R&D | Sold on the market10b5-1 plan | −4,627 | $331.34average | $1.5M | Form 4 ↗ |
| Feb 23, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Award | +158 | — | — | Form 4 ↗ |
| Feb 17, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Sold on the market10b5-1 plan | −2,041 | $331.96 | $678K | Form 4 ↗ |
| Feb 13, 2026 | Garg PushkalEVP Chief R&D | Sold on the market | −2,242 | $310.08 | $695K | Form 4 ↗ |
| Feb 13, 2026 | Greenstreet YvonneCEO, Director | Sold on the market | −6,958 | $310.08 | $2.2M | Form 4 ↗ |
| Feb 13, 2026 | Tanguler TolgaEVP, Chief Commercial Officer | Sold on the market | −1,959 | $310.08 | $607K | Form 4 ↗ |
| Feb 13, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Sold on the market10b5-1 plan | −1,959 | $310.08 | $607K | Form 4 ↗ |
| Feb 13, 2026 | Poulton Jeffrey V.EVP, CFO | Sold on the market | −2,242 | $310.08 | $695K | Form 4 ↗ |
| Feb 12, 2026 | Garg PushkalEVP Chief R&D | Award | +4,579 | — | — | Form 4 ↗ |
| Feb 12, 2026 | Greenstreet YvonneCEO, Director | Award | +14,209 | — | — | Form 4 ↗ |
| Feb 12, 2026 | Tanguler TolgaEVP, Chief Commercial Officer | Award | +4,000 | — | — | Form 4 ↗ |
| Feb 12, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Award | +4,000 | — | — | Form 4 ↗ |
| Feb 12, 2026 | Poulton Jeffrey V.EVP, CFO | Award | +4,579 | — | — | Form 4 ↗ |
| Jan 12, 2026 | Garg PushkalEVP Chief R&D | Sold on the market | −1,510 | $362.87average | $548K | Form 4 ↗ |
| Jan 12, 2026 | Greenstreet YvonneCEO, Director | Sold on the market | −9,577 | $362.86average | $3.5M | Form 4 ↗ |
| Jan 12, 2026 | Poulton Jeffrey V.EVP, CFO | Sold on the market | −2,780 | $362.87average | $1.0M | Form 4 ↗ |
| Jan 12, 2026 | Tanguler TolgaEVP, Chief Commercial Officer | Sold on the market | −1,510 | $362.87average | $548K | Form 4 ↗ |
| Jan 11, 2026 | Garg PushkalEVP Chief R&D | Award | +3,800 | — | — | Form 4 ↗ |
| Jan 11, 2026 | Greenstreet YvonneCEO, Director | Award | +19,003 | — | — | Form 4 ↗ |
| Jan 11, 2026 | Poulton Jeffrey V.EVP, CFO | Award | +6,193 | — | — | Form 4 ↗ |
| Jan 11, 2026 | Tanguler TolgaEVP, Chief Commercial Officer | Award | +3,800 | — | — | Form 4 ↗ |
SEC Form 4, public domain. The latest 40 of 45 Form 4 filings from the last 12 months are counted. A sale filled at several prices is one line at its average price. All Form 4s on EDGAR
Beat the forecast in 3 of the last 4 quarters.
The stock's move is from the close before the report to the close after it.